Tesamorelin Vs Semaglutide
Tesamorelin vs Semaglutide
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
Tesamorelin vs semaglutide compares two opposite fat-loss agents, and tesamorelin is a GHRH analog studied for visceral fat. In a phase 3 trial it reduced visceral adipose tissue by about 15.2 percent versus placebo (Falutz et al., 2007).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the core difference between tesamorelin and semaglutide?
They target fat through opposite mechanisms: tesamorelin stimulates growth hormone release to reduce visceral fat, while semaglutide mimics GLP-1 to reduce appetite and total body weight.
Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH). It signals the pituitary to release the body's own growth hormone, which in turn affects fat metabolism. In its phase 3 program, tesamorelin lowered visceral adipose tissue by about 15.2 percent compared with placebo (Falutz et al., 2007). It carries an approved indication (marketed as Egrifta) for reducing excess visceral abdominal fat in a specific patient population.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It slows gastric emptying and acts on appetite centers, which lowers food intake. In the STEP 1 trial, participants on semaglutide lost about 15 percent of body weight, a mean of roughly 15.3 kg, versus placebo (Wilding et al., 2021).
The short version: one raises a growth-axis signal to shift visceral fat, the other quiets hunger to shift overall weight.
How do tesamorelin and semaglutide compare side by side?
Tesamorelin was studied against a visceral fat endpoint, semaglutide against a total body weight endpoint, so their trial results are not directly interchangeable.
| Factor | Tesamorelin | Semaglutide |
|---|---|---|
| Class | GHRH analog | GLP-1 receptor agonist |
| Mechanism | Stimulates the body's own growth hormone release | Mimics GLP-1, slows gastric emptying, reduces appetite |
| Fat compartment studied | Visceral adipose tissue, about 15.2 percent reduction (Falutz et al., 2007) | Total body weight, about 15 percent, roughly 15.3 kg (Wilding et al., 2021) |
| Approval framing | Approved indication for excess visceral abdominal fat (Egrifta) | Approved for chronic weight management |
| Reported side effects | Injection-site reactions, joint symptoms, fluid retention reported in trials (Falutz et al., 2007) | Nausea, vomiting, diarrhea common in GLP-1 trials (Wilding et al., 2021) |
| Regain after stopping | Not the focus of the primary trial | Meaningful regain reported after withdrawal (Wilding et al., 2022) |
What dose ranges did the trials report?
In the published trials, participants received fixed regimens set by the study protocol, not a personalized dose. What follows describes trial design only. Your personal dose is a clinician's decision.
| Compound | Research-reported regimen | Source |
|---|---|---|
| Tesamorelin | 2 mg daily subcutaneous in the phase 3 visceral fat program | Falutz et al., 2007 |
| Semaglutide | Titrated to 2.4 mg once weekly subcutaneous in STEP 1 | Wilding et al., 2021 |
These figures are reported from the named trials. They are not a recommendation, a starting point, or a schedule. Route any decision about use to a qualified clinician.
What about half-life and dosing frequency?
Tesamorelin was studied as a daily injection, while semaglutide was studied as a once-weekly injection, reflecting different pharmacokinetics.
Tesamorelin has a short circulating half-life and was dosed daily in its trial program (Falutz et al., 2007). Semaglutide has a long half-life that supports once-weekly dosing, which is how it was given in STEP 1 (Wilding et al., 2021). This is one of the clearest practical contrasts between the two: frequency of administration in the studies.
Which one is the right comparison for a given research question?
It depends on the endpoint: tesamorelin trials answer a visceral fat question, semaglutide trials answer a total body weight question.
If the research interest is specifically visceral adipose tissue, the tesamorelin literature is the direct match, since its phase 3 endpoint was VAT reduction of about 15.2 percent (Falutz et al., 2007). If the interest is overall body weight change, the semaglutide literature is the direct match, with about 15 percent mean loss in STEP 1 (Wilding et al., 2021).
They are not competitors on the same endpoint. One outcome that matters across both: semaglutide trials show meaningful weight regain after the drug is stopped (Wilding et al., 2022), a durability question the tesamorelin primary trial was not designed to answer. Any comparison for a personal situation belongs with a qualified clinician who can weigh mechanism, indication, and safety.
Keep reading
Related research and verification
Tesamorelin Vs Semaglutide: FAQ
Is tesamorelin the same class as semaglutide?
No. Tesamorelin is a GHRH analog that acts on the growth hormone axis (Falutz et al., 2007). Semaglutide is a GLP-1 receptor agonist that acts on appetite (Wilding et al., 2021). Different classes, different targets.
Which one showed more fat loss in trials?
They measured different things. Tesamorelin reduced visceral adipose tissue by about 15.2 percent (Falutz et al., 2007). Semaglutide reduced total body weight by about 15 percent (Wilding et al., 2021). The percentages are not directly comparable because the endpoints differ.
Do people regain weight after stopping either one?
Semaglutide trials report meaningful regain after withdrawal (Wilding et al., 2022). The tesamorelin primary trial did not center on regain, so there is less published data on that specific question.
What side effects did the trials report?
Tesamorelin trials reported injection-site reactions, joint symptoms, and fluid retention (Falutz et al., 2007). Semaglutide trials reported nausea, vomiting, and diarrhea as common (Wilding et al., 2021).
Can these be combined?
There is no completed head-to-head or combination trial named here to support that, so any claim about combining them would go beyond the published data. This is a clinician question, not a self-directed one.
Are these approved products?
Tesamorelin has an approved indication for excess visceral abdominal fat (marketed as Egrifta). Semaglutide has an approved indication for chronic weight management. Approval status and access rules vary by setting.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.